NLS Pharmaceutics Ltd (NASDAQ: NLSP) has seen a decline in its stock price by -13.63 in relation to its previous close of 3.03. However, the company has experienced a -26.49% decline in its stock price over the last five trading sessions. accesswire.com reported 2024-11-18 that ZÜRICH, SWITZERLAND / ACCESSWIRE / November 18, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(NASDAQ:NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, provided insights today into the preclinical program evaluating its dual orexin receptor agonist (DOXA) platform.
Is It Worth Investing in NLS Pharmaceutics Ltd (NASDAQ: NLSP) Right Now?
Company’s 36-month beta value is -0.52.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for NLSP is 1.63M, and currently, short sellers hold a 3.43% ratio of that floaft. The average trading volume of NLSP on December 03, 2024 was 215.82K shares.
NLSP’s Market Performance
NLSP’s stock has seen a -26.49% decrease for the week, with a -27.31% drop in the past month and a -54.88% fall in the past quarter. The volatility ratio for the week is 8.72%, and the volatility levels for the past 30 days are at 11.36% for NLS Pharmaceutics Ltd The simple moving average for the past 20 days is -25.29% for NLSP’s stock, with a -61.62% simple moving average for the past 200 days.
NLSP Trading at -38.15% from the 50-Day Moving Average
After a stumble in the market that brought NLSP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -89.25% of loss for the given period.
Volatility was left at 11.36%, however, over the last 30 days, the volatility rate increased by 8.72%, as shares sank -42.14% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -53.17% lower at present.
During the last 5 trading sessions, NLSP fell by -28.65%, which changed the moving average for the period of 200-days by -86.20% in comparison to the 20-day moving average, which settled at $3.50. In addition, NLS Pharmaceutics Ltd saw -88.91% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for NLSP
The total capital return value is set at 0.32.
Based on NLS Pharmaceutics Ltd (NLSP), the company’s capital structure generated -0.23 points at debt to capital in total, while cash flow to debt ratio is standing at -0.89. The debt to equity ratio resting at -0.18. The interest coverage ratio of the stock is -8.87.
Currently, EBITDA for the company is -11.8 million with net debt to EBITDA at -0.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.15.
Conclusion
In a nutshell, NLS Pharmaceutics Ltd (NLSP) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
